A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies

Clinical trial NCT07231458 · RECRUITING

Trial details

NCT number: NCT07231458
Sponsor: Abalos Therapeutics GmbH
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumors

Start date: 2025-10-14
Primary completion: 2026-10-30
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.